TrialExperimental dermatology2022

IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study.

Alexa B Kimball et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.